It's How Medicine Should Be®


French German Italian Portuguese Russian

Atopic Dermatitis Treatment Study

Clinical Trial Title: 
Multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of mepolizumab administered subcutaneously in subjects with moderate to severe atopic dermatitis.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Michael D. Tharp, MD
Clinical Trial Protocol Description: 

Rush Dermatology seeks volunteers with a diagnosis of moderate to severe atopic dermatitis (eczema) for a clinical trial testing an investigational medication. All office visits and treatments are provided free of charge.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between 12 and 70 years of age.
  • Have a diagnosis of moderate to severe atopic dermatitis (eczema) for at least 2 years.
  • Have had an inadequate response to topical medications.
  • Have at least 10% of the skin affected by atopic dermatitis (eczema).

This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Clinical Trial Area: 
Contact Email: 
Contact Phone: 
(312) 563-4001
Contact Name: 
Carmen Petrizzo or Danica Uzelac